Pfizer begins phase III trial for vaccine against RSV

On the day after Bavarian Nordic received the promising results from the phase II trial for its vaccine against the RS virus, Pfizer announces its own vaccine candidate entering phase III.

Photo: Mike Blake/REUTERS / X00030

US pharmaceutical giant Pfizer enters phase III with its vaccine candidate against the RS virus, the company announces in a press release today.

The statement comes just one day after Bavarian Nordic cheered the results of its phase II study of the Danish vaccine candidate.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs